Clinical trials: PD
Acne
Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne
This is a 4-part study. Part A will be a randomized, double-blind, placebo-controlled investigation of single ascending doses (SAD) to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) biomarkers of…
- Trial name
- NCT06989840
- Testing
- TVB-3567
- Where
- 6 sites in United States, Australia
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Sagimet Biosciences Inc.
Parkinson's Disease
GDNF Gene Therapy for Parkinson's Disease
The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.
- Trial name
- NCT04167540
- Testing
- AAV2-GDNF
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brain Neurotherapy Bio, Inc.
Lung Cancer
Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC)…
- Trial name
- NCT03322540
- Testing
- Pembrolizumab, Epacadostat
- Where
- 101 sites in United States, Australia and 16 more
- Volunteers
- 154 people
- Sponsor
- Incyte Corporation
Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
This multiple-center, 3-part, single-blind dose escalation (Part A), randomized, double-blind (Part B), and open-label multiple dose extension (Part C) study will be conducted in male and female subjects with neurogenic…
- Conditions
- Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease
- Trial name
- NCT02705755
- Testing
- TD-9855
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Theravance Biopharma
PHA1A
Tolerance, PK and PD Effects Study of TPN-672 in Chinese Healthy Volunteers
This is a single-site, randomized, double-blind, placebo-controlled, incremental phase I clinical trial to evaluate preliminarily the tolerance, pharmacokinetics and pharmacodynamic effects of TPN672 maleate in Chinese healthy…
- Trial name
- NCT03931668
- Testing
- TPN-672
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Cancer, Rare Disease
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
This is an investigator initiated single institution, open-label study to evaluate the antitumor activity, safety, and tolerability of durvalumab in combination with tremelimumab in subjects with select advanced rare solid tumors.
- Trial name
- NCT02938793
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Prisma Health-Upstate
HIV Infections
Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression
In HIV-infected patients, enhanced PD-1 expression of T cells correlates with T cell depletion, as evidenced by reduced virus-specific proliferative capacity and decreased cytokine expression.Targeting PD-L1 drugs to block…
- Trial name
- NCT05129189
- Testing
- ASC22 group
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Public Health Clinical Center
Non-Small-Cell Lung Carcinoma
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
This is a Japan Extension Study of Global Study MK-3475-189 (NCT02578680). This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy…
- Trial name
- NCT03950674
- Testing
- Pembrolizumab 200 mg, Cisplatin, Carboplatin
- Where
- 10 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer
HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
Background: For some cancers associated with human papillomavirus (HPV), standard treatments are not helpful. Researchers want to see if a vaccine for HPV combined with a drug called M7824 (MSB0011359C) has a better effect on…
- Conditions
- HPV Positive Cancer, Vulvar, Vaginal, Penile, Rectal Cancer, Anal Cancer, Oropharyngeal Cancer
- Trial name
- NCT04432597
- Testing
- PRGN-2009, M7824, EKG
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Allergic Rhinoconjunctivitis
Study of BLU-808 in Allergic Rhinoconjunctivitis
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of BLU-808 in participants with ragweed (Ambrosia artemisiifolia)-induced allergic…
- Trial name
- NCT06922448
- Testing
- BLU-808
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Blueprint Medicines Corporation
Non Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma
Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC
This Phase II trial is to see how well single agent chemotherapy and pembrolizumab work elderly patients (≥ 75 years) with advanced non small cell lung cancer (NSCLC).
- Conditions
- Non Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, PD-L1 Gene Mutation
- Trial name
- HFHS 21-01 (NCT04754815)
- Testing
- Pembrolizumab, Pemetrexed, Paclitaxel
- Sponsor
- Shirish Gadgeel
Type 2 Diabetes, Insulin Resistance
PK/PD Study of U-500 Regular Insulin
The purpose of this study is to learn more about how U500 regular insulin can be effectively be used to treat type 2 diabetes. Most insulin treated patients with type 2 diabetes take U100 insulin, but if they require large doses…
- Conditions
- Type 2 Diabetes, Insulin Resistance, High Insulin Requirements
- Trial name
- NCT02148250
- Testing
- U-500 insulin, 100 syringe units, U-500 insulin, 200 syringe units
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Minnesota
Advanced Cancer, Pleural Effusion
Intrapleural Catheter Daily Versus Three Times a Week Drainage
The goal of this clinical research study is to learn if draining the IPC every day is better at than draining it 3 times a week.
- Trial name
- NCT00761618
- Testing
- Intrapleural catheter (IPC) drained, IPC Placement, Chest X-Ray
- Where
- United States
- Volunteers
- 257 people
- Sponsor
- M.D. Anderson Cancer Center
Parkinson Disease
Immersive Virtual Reality Bicycling for Persons With Parkinson's Disease
This study has three objectives about persons with Parkinson's Disease during bicycling: 1. Determine the effect of visual feedback and competition during virtual bicycling on neuromuscular and cardiovascular intensity 2.
- Trial name
- NCT05160025
- Testing
- Virtual reality bicycling
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Rutgers, The State University of New Jersey
Parkinson Disease
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of…
- Trial name
- PPMI (NCT04477785)
- Where
- 50 sites in United States, Austria and 10 more
- Volunteers
- 4,500 people, healthy volunteers welcome
- Sponsor
- Michael J. Fox Foundation for Parkinson's Research
Healthy Adult Premenopausal Female Volunteers
Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects
A Phase 1, randomized, double-blind, placebo-controlled, crossover study to assess the effect of ITCA 650 on the pharmacokinetics (PK) of once daily administration of Levora® (ethinyl estradiol 0.3 mg (EE) and levonorgestrel 0.15…
- Trial name
- NCT02641990
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Intarcia Therapeutics
Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
This phase III trial compares the effectiveness of pembrolizumab and sacituzumab govitecan-hziy to standard of care in treating patients with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced) or…
- Conditions
- Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Trial name
- NCT06524544
- Testing
- Biospecimen Collection, Carboplatin, Cisplatin
- Where
- 162 sites in United States
- Volunteers
- 320 people
- Sponsor
- National Cancer Institute (NCI)
ESRD, Disorders Associated With Peritoneal Dialysis
Peritoneal Dialysis Registration System (PERSIST)
Brief Summary: The investigators are registering all PD patients at recruited hospitals and developing a PD database in China. Patients will be followed up every 3 months, and both baseline and follow-up information will be…
- Trial name
- NCT02989298
- Testing
- No intervention
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Sun Yat-sen University
Bladder, Neurogenic
PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder
Aims of this study is to characterize the pharmacokinetic/pharmacodynamic profile and evaluate the safety, efficacy and tolerability, of tamsulosin hydrochloride as treatment in children with a neuropathic bladder, over the…
- Trial name
- NCT00340704
- Testing
- tamsulosin hydrochloride
- Where
- 72 sites in United States, Belgium and 12 more
- Volunteers
- 143 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Hepatocellular
A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Failed…
- Trial name
- NCT06742892
- Testing
- HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Henlius Biotech